Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Small Cell Lung Carcinoma 15Recurrence 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Unresectable Locally Advanced or Metastatic Solid Tumors 1Squamous Cell Carcinoma of Head and Neck 1SCLC, Extensive Stage 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Medulloblastoma 1Lung 1Leukemia 1Head and Neck Neoplasms 1Extrapulmonary Neuroendocrine Cancer 1Extensive Stage Lung Small Cell Cancer 1Extensive Small Cell Lung Cancer 1Ependymoma 1ES-SCLC 1Carcinoma, Squamous Cell 1Carcinoma, Small Cell 1Carcinoma, Pancreatic Ductal 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Extrapulmonary Neuroendocrine Cancer × Etoposide × Clear all
NCT07544654 2026-05-27

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Boehringer Ingelheim

Phase 3 Not yet recruiting
390 enrolled
Endocrine

Extrapulmonary Neuroendocrine Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡